BioStem Technologies (BSEM) vs Elicio Therapeutics (ELTX)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 8, 2026.
Summary
BioStem Technologies (BSEM) has outperformed Elicio Therapeutics (ELTX) over the past year, losing 45.0% versus a loss of 82.8%. Over five years, BSEM leads with a +88.6% price change compared with -97.9% for ELTX. BioStem Technologies is the larger company by market cap ($49.3 million vs $47.6 million), about 1.0 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | BSEM | ELTX |
|---|---|---|
| Share price | $2.64 | $1.81 |
| Market cap | $49.29M | $47.57M |
| 1-day change | +10.46% | -2.16% |
| YTD return | -30.71% | -77.26% |
| 1-year return | -45.00% | -82.79% |
| 5-year return | +88.57% | -97.92% |
| P/E ratio (TTM) | 3.00 | — |
| Forward P/E | 9.10 | — |
| EPS (TTM) | $0.88 | $-2.16 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $8.40 | $16.00 |
| 52-week low | $2.25 | $1.71 |
| Distance from 52-week high | -68.57% | -88.69% |
| Analyst consensus | none | strong_buy |
| Avg. price target upside | +165.15% | +655.25% |
| Average volume | 120.39K | 352.93K |
| Shares outstanding | 18.67M | 26.28M |
| Employees | 73 | 33 |
| Sector | Healthcare | Healthcare |
| Industry | Biotechnology | Biotechnology |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- BSEM has outperformed ELTX by 37.8 percentage points over the past year.
About BioStem Technologies
BSEM stock →BioStem Technologies, Inc. engages in the development, manufacturing, and commercialization of placental-derived allografts for advanced wound care and regenerative therapies in the United States.
Healthcare · Biotechnology · 73 employees
About Elicio Therapeutics
ELTX stock →Elicio Therapeutics, Inc., a clinical-stage biotechnology company, develops immunotherapies for the treatment of cancer. Its lead product candidate, ELI-002, is a multivalent lymph node-targeted amphiphile (AMP) peptide vaccine that is in Phase II clinical trials for seven Kirsten rat sarcoma viral oncogene homolog driver mutations.
Healthcare · Biotechnology · 33 employees
BSEM vs ELTX FAQ
Which is bigger, BioStem Technologies or Elicio Therapeutics?
BioStem Technologies (BSEM) is larger, with a market capitalization of $49.29M compared with $47.57M for Elicio Therapeutics (ELTX).
Which stock has performed better over the past year, BSEM or ELTX?
BSEM returned -45.00% over the past 12 months, compared with -82.79% for ELTX (price return, excluding dividends). Past performance does not predict future results.
Are BioStem Technologies and Elicio Therapeutics in the same industry?
Yes. Both are classified in the Biotechnology industry within the Healthcare sector.